Obstetrics/Gynecology General
RSSArticles
-
Targeting Vasomotor Symptoms with a Neurokinin-3 Receptor Antagonist
A meta-analysis of five randomized controlled studies showed that fezolinetant improved moderate-to-severe vasomotor symptoms with a pooled mean difference of 2.62 episodes per day (95% confidence interval [CI], 1.85-3.41) and had no significant adverse effects compared to placebo (odds ratio, 1.01; 95% CI, 0.84-1.22).
-
Safety of Non-Insulin Antidiabetic Medications in Early Pregnancy
A multinational cohort study of more than 50,000 pregnant people found that those with periconceptual use of non-insulin antidiabetic medications, such as sulfonylureas, dipeptidyl peptidase 4 inhibitors, glucagon-like peptide 1 agonists, or sodium-glucose cotransporter 2 inhibitors, did not have increased risk of congenital malformations compared to those who used insulin periconceptually.
-
Estradiol Valerate-Dienogest and VTE Risk in Combined Oral Contraceptives
A pooled analysis comparing the risk of venous thromboembolism associated with combined oral contraceptives (COC) found significantly decreased venous thromboembolism risk in estradiol valerate-dienogest COCs compared with ethinyl estradiol-levonorgestrel COCs (propensity score-stratified hazard ratio, 0.46; 95% confidence interval, 0.22-0.98).
-
Progestins and Meningioma Risk: What Do the Data Say?
The authors of this study sought to determine whether there was a relationship between progestins and central nervous system meningiomas.
-
Medication Abortion via Telehealth in the United States
A prospective study of U.S. patients obtaining medication abortion through telehealth platforms demonstrated high effectiveness (97.7%; 95% confidence interval [CI], 97.2% to 98.1%) and safety (99.8%; 95% CI, 99.6% to 99.9%).
-
The Role of Probiotics and Synbiotics for Management of Gestational Diabetes
Probiotics and synbiotics have shown promise in reducing insulin resistance and enhancing glycemic control, blood lipid profiles, and inflammation among women with gestational diabetes mellitus (GDM). Although they hold potential as a treatment option for GDM, conclusive recommendations await larger, well-designed randomized controlled trials with extended follow-up periods.
-
Stopping STI Epidemic Requires More Testing, More Public Resources
Syphilis cases continue to climb in the years following the COVID-19 pandemic, and public health programs and clinicians struggle to reverse this trend.
-
Researchers: Studies Cited in Court Cases on Abortion and Mental Health Impact Are Flawed
As the U.S. Supreme Court considers a case involving the abortion medication mifepristone and whether it was properly approved by the Food and Drug Administration, justices will see mention of research about abortion from flawed studies, including some that have been retracted.
-
Supplemental Calcium Therapy for the Prevention of Preeclampsia and Preterm Birth
In pregnancy, calcium supplementation was well tolerated and reduced the risk of preeclampsia and preterm birth, with no significant differences observed between low-dose and high-dose supplementation.
-
Medications for OUD in the First Trimester and Congenital Malformation Risk
In this large, retrospective cohort study of births covered by Medicaid from 2000-2018, the authors used linked Medicaid use data to compare 9,514 pregnancies with buprenorphine exposure and 3,846 with methadone exposure in the first trimester. After adjusting for relevant confounders, the risk of major congenital malformation was lower for buprenorphine-exposed infants compared to methadone-exposed infants (risk ratio, 0.82; 95% confidence interval, 0.69-0.97), although rates overall remained low (50.9 per 1,000 for buprenorphine and 60.6 per 1,000 for methadone).